| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.34 μM (PKC-iota)[1]
PKC-iota inhibitor 1 targets protein kinase C-iota (PKC-ι), a member of the atypical protein kinase C (aPKC) family that plays critical roles in cell polarity, proliferation, and survival. PKC-ι is frequently overexpressed or hyperactivated in various cancers and is implicated in tumor growth and metastasis. Inhibition of PKC-ι by this compound disrupts downstream signaling pathways involved in oncogenesis. |
|---|---|
| ln Vitro |
PKC-iota inhibitor 1 demonstrates potent in vitro inhibition of PKC-ι with an IC50 of 0.34 μM. The compound's activity has been characterized in biochemical assays using purified enzyme preparations. Its selectivity for PKC-ι over other protein kinase C isoforms and related kinases has been demonstrated. The compound shows clearance rates of 71.0 mL·min⁻¹·g⁻¹ in mouse liver microsomes and 5.1 mL·min⁻¹·g⁻¹ in human liver microsomes.
|
| ln Vivo |
In vivo activity of PKC-iota inhibitor 1 has been suggested by its potential for cancer research. The compound's favorable clearance profile in liver microsomes suggests potential for in vivo studies. Further in vivo studies in animal models of cancer are needed to evaluate its antitumor efficacy, pharmacokinetic properties, and safety profile.
|
| Enzyme Assay |
In vitro enzyme assays for PKC-iota inhibitor 1 involve measuring its inhibition of PKC-ι kinase activity. The assay typically uses purified recombinant PKC-ι and a peptide substrate, with kinase activity measured by detecting phosphorylation using radioactive ATP or fluorescence-based methods. The IC50 value of 0.34 μM is determined from dose-response curves generated in these enzymatic assays.
|
| Cell Assay |
In vitro cellular assays for PKC-iota inhibitor 1 involve treating cancer cell lines with varying concentrations of the compound and measuring cell proliferation, survival, or downstream signaling markers. The compound's ability to inhibit PKC-ι activity in cells can be assessed by evaluating the phosphorylation status of PKC-ι substrates or downstream signaling pathway components such as NF-κB.
|
| Animal Protocol |
In vivo animal experiments for PKC-iota inhibitor 1 would typically involve administering the compound to tumor-bearing mouse models. Efficacy is evaluated by measuring tumor growth inhibition, survival rates, and biomarker changes. The compound's pharmacokinetic properties, including its clearance rate in mouse liver microsomes, would inform dosing regimens for in vivo studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for PKC-iota inhibitor 1 indicate a clearance rate of 71.0 mL·min⁻¹·g⁻¹ in mouse liver microsomes and 5.1 mL·min⁻¹·g⁻¹ in human liver microsomes. The compound is soluble in DMSO at 125 mg/mL (333.83 mM). Powder should be stored at -20°C for up to 3 years, and solutions at -80°C for up to 2 years. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for PKC-iota inhibitor 1 are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only and is not for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
PKC-iota inhibitor 1 (CAS#: 2328094-11-5) has the molecular formula C21H22N6O and a molecular weight of 374.44. Its chemical name is 2-amino-5-(3-(piperazin-1-yl)phenyl)-N-(pyridin-4-yl)nicotinamide. The compound is a potent PKC-ι inhibitor (IC50 = 0.34 μM) used in cancer research. Purity is ≥98%.
|
| Molecular Formula |
C21H22N6O
|
|---|---|
| Molecular Weight |
374.438983440399
|
| Exact Mass |
374.185
|
| CAS # |
2328094-11-5
|
| PubChem CID |
138377600
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
505
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C(N)N=CC(=C1)C1=CC=CC(=C1)N1CCNCC1)NC1C=CN=CC=1
|
| InChi Key |
YDMJAALVMGFGRY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22N6O/c22-20-19(21(28)26-17-4-6-23-7-5-17)13-16(14-25-20)15-2-1-3-18(12-15)27-10-8-24-9-11-27/h1-7,12-14,24H,8-11H2,(H2,22,25)(H,23,26,28)
|
| Chemical Name |
2-amino-5-(3-piperazin-1-ylphenyl)-N-pyridin-4-ylpyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (333.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6707 mL | 13.3533 mL | 26.7065 mL | |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3413 mL | |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
